Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Birth control pills may tighten knees, new study suggests

NCT ID NCT06504953

Knowledge-focused Sponsor: Centre Hospitalier Universitaire de Nice Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 11, 2026 · Updated 2 times

Summary

This study looks at how different types of hormone therapy (like birth control pills) affect knee looseness in healthy women aged 18-40. Researchers will measure knee movement using a special device. The goal is to understand why women have a higher risk of ACL injuries and whether hormones play a role.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

72 people

The number who actually took part.

Started

Aug 2024

Finished

Jun 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 40 years

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Female between 18 and 40 years of age; * No history of surgery on the 2 lower limbs; * No change in contraceptive method in the last 6 months; * Signature of informed consent ; * Social security affiliation; * D14 of her menstrual cycle (+/-1 day) (the first day of the cycle (D1) being considered as the first day of menstruation), except for those on unregulated micro-progestogen contraception. Exclusion Criteria: * Pregnancy or breastfeeding (check with urine pregnancy test); * Menopause; * Surgery: tubal ligation, oophorectomy, adnexectomy, hysterectomy; * History of inflammatory joint disease, systemic or localized to the knee; * History of microcrystalline or infectious pathology localized to the knee; * History of fracture, severe sprain or dislocation of the knee joint; * History of osteoarticular or congenital diseases that may lead to ACL laxity (e.g. Marfan syndrome, trisomy 21, Ehlers-Danlos syndrome, etc.); * Signs of hyperlaxity (Beighton test \> 4); * BMI \> 25 ; * Daily alcohol consumption above the thresholds recommended by Public Health in France (more than 2 glasses per day); * Intense or unusual physical exercise during the last 72 hours before the inclusion visit; * Inability to understand the protocol; * Women under guardianship, curatorship or deprived of liberty.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hormone are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hormone Tibial translation Women

Contacts and locations

Locations

  • CHU Nice - Hôpital de l'Archet 2

    Nice, Alpes-Maritimes, 06200, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.